Valbiotis SA (DE:8JD)
FRANKFURT:8JD
Want to see DE:8JD full AI Analyst Report?
8JD Stock Chart & Stats
€0.67
-€0.01(-0.67%)
At close: 4:00 PM EST
€0.67
-€0.01(-0.67%)
Day’s Range― - ―
52-Week Range€0.53 - €1.29
Previous CloseN/A
Volume0.00
Average Volume (3M)407.00
Market Cap
€24.87M
Enterprise Value€21.25M
Total Cash (Recent Filing)€8.68M
Total Debt (Recent Filing)€5.09M
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding23,698,235
10 Day Avg. Volume1,223
30 Day Avg. Volume407
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.36
Price to Sales (P/S)18.17
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.36
Revenue Forecast (FY)€4.53M
Bulls Say, Bears Say
Bulls Say
Top-line ReboundA marked revenue rebound in 2025 (Fundamentals revenue growth ~417%) indicates the company can generate meaningful sales when commercialization initiatives succeed. Over a 2–6 month horizon this suggests recoverable demand and the ability to scale product distribution, reducing single-period revenue risk if management sustains commercial execution and distribution channels.
Structural Market PositioningValbiotis targets preventive metabolic and cardiovascular nutraceuticals, a segment benefiting from secular trends in preventive health, aging populations, and consumer wellness spending. This durable market positioning supports recurring consumer demand and licensing opportunities, underpinning long-term revenue potential beyond short-term product cycles.
Manageable LeverageReported leverage sits in a moderate range (~0.35–0.98 historically, ~0.73 in 2025), meaning the company is not highly indebted on paper. This structural capital position gives management room to pursue partnerships, licensing, or incremental financing to support commercialization without immediate insolvency pressure, assuming cash burn is addressed.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow (FCF ~-€8.2M in 2025) creates an ongoing dependency on external capital. Over several months this elevates dilution risk, constrains strategic flexibility, and can force prioritization of near-term liquidity actions over long-term R&D or commercial investments, undermining sustainable growth plans.
Sustained UnprofitabilityThe company reports persistent operating and net losses and negative gross profit in the latest years, indicating current revenues do not cover direct costs. Structurally weak margins demand either substantial revenue scale, cost restructuring, or price/product mix improvement to become profitable; absent that, losses may persist and erode shareholder value.
Declining Equity And AssetsDeclines in equity and total assets reduce balance-sheet flexibility and reflect accumulated losses. Persistently negative returns on equity signal value dilution; structurally, this limits ability to raise non-dilutive capital, increases financing costs, and heightens vulnerability to adverse shocks unless profitability or cash flows materially improve.
Valbiotis SA News
8JD FAQ
What was Valbiotis SA’s price range in the past 12 months?
Valbiotis SA lowest stock price was €0.53 and its highest was €1.29 in the past 12 months.
What is Valbiotis SA’s market cap?
Valbiotis SA’s market cap is €24.87M.
When is Valbiotis SA’s upcoming earnings report date?
Valbiotis SA’s upcoming earnings report date is Sep 24, 2026 which is in 126 days.
How were Valbiotis SA’s earnings last quarter?
Valbiotis SA released its earnings results on Mar 02, 2026. The company reported -€0.204 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.204.
Is Valbiotis SA overvalued?
According to Wall Street analysts Valbiotis SA’s price is currently Overvalued.
Does Valbiotis SA pay dividends?
Valbiotis SA does not currently pay dividends.
What is Valbiotis SA’s EPS estimate?
Valbiotis SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valbiotis SA have?
Valbiotis SA has 23,698,235 shares outstanding.
What happened to Valbiotis SA’s price movement after its last earnings report?
Valbiotis SA reported an EPS of -€0.204 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.309%.
Which hedge fund is a major shareholder of Valbiotis SA?
Currently, no hedge funds are holding shares in DE:8JD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valbiotis SA
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.